Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)
Status:
Withdrawn
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the protocol is to evaluate the correlation between plasma lanreotide levels
and Growth Hormone (GH)/Insulin Like Growth Factor 1 (IGF-1) dynamics and clinical
improvement in patients with acromegaly treated with lanreotide Autogel (Somatuline ATG)